Sage's Phase III epilepsy readout delayed

Sage Therapeutics Inc. (NASDAQ:SAGE) slipped $5.60 (13%) to $36.86 on Tuesday after disclosing that it plans to report data from a Phase III epilepsy study of SAGE-547 later than it had anticipated. The company said patient enrollment in the study is occurring more slowly than expected.

The company now expects data from the Phase III STATUS study in 1H17, rather than this half. The trial is evaluating the positive allosteric modulator (PAM) of GABA A receptor to treat super-refractory status epilepticus. ...